(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/147418 A1

(51) International Patent Classification:

C07D 401/14 (2006.01)	*C07D 491/04* (2006.01)
C07D 403/14 (2006.01)	*C07D 491/10* (2006.01)
C07D 405/14 (2006.01)	*C07D 495/04* (2006.01)
C07D 413/14 (2006.01)	*C07D 498/04* (2006.01)
C07D 471/04 (2006.01)	*A61P 35/00* (2006.01)
C07D 487/04 (2006.01)	*A61K 31/501* (2006.01)

(21) International Application Number:
PCT/US2023/061372

(22) International Filing Date:
26 January 2023 (26.01.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/304,093	28 January 2022 (28.01.2022)	US
63/378,647	06 October 2022 (06.10.2022)	US
63/385,303	29 November 2022 (29.11.2022)	US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **CHANDRASEKHAR, Jayaraman**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **CHANG, Jonah J.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **CURRIE, Kevin S.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **HOLMBO, Stephen D.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **JACOBSEN, Jesse M.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **KUKLA, David L.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **LEE, Seung H.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **MOAZAMI, Yasamin**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **PATEL, Leena B.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **PAUL, Thomas J.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **PERREAULT, Stephane**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **SALVO, Patrick J.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **TREIBERG, Jennifer A.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **WEAVER, Heath A.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **POLSTER, Philip B.** et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: PARP7 INHIBITORS



(I)

(57) Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

WO 2023/147418 A1